Low-dose nab-paclitaxel-based combination chemotherapy in heavily pretreated pancreatic cancer patients
ConclusionIn heavily pretreated pancreatic adenocarcinoma patients, low-dose nab-paclitaxel-based chemotherapy was fairly tolerable with modest efficacy.
Source: Journal of the Formosan Medical Association - Category: General Medicine Source Type: research
More News: Adenocarcinoma | Anemia | Cancer | Cancer & Oncology | Chemotherapy | General Medicine | Pancreas | Pancreatic Cancer | Study | Toxicology